Rongchang Biotech announced that the company signed a “license agreement” with the related party Rongchang Pharmaceutical and was granted the right to monopolize, irrevocable, and multi-level sub-licenses for pan-RAS small molecule inhibitors and their products, and can carry out R&D, production, and commercialization activities. The company is required to pay a down payment of 50 million yuan, a maximum milestone payment of 4.870 billion yuan, and royalties based on 3%-7% of annual net sales. This transaction constitutes a related transaction and does not constitute a major asset restructuring. It has been reviewed and approved by the company's board of directors, and still needs to be submitted to the shareholders' meeting for consideration.

Rongchang Biotech announced that the company signed a “license agreement” with the related party Rongchang Pharmaceutical and was granted the right to monopolize, irrevocable, and multi-level sub-licenses for pan-RAS small molecule inhibitors and their products, and can carry out R&D, production, and commercialization activities. The company is required to pay a down payment of 50 million yuan, a maximum milestone payment of 4.870 billion yuan, and royalties based on 3%-7% of annual net sales. This transaction constitutes a related transaction and does not constitute a major asset restructuring. It has been reviewed and approved by the company's board of directors, and still needs to be submitted to the shareholders' meeting for consideration.